Senores Pharmaceuticals

517.05
-15.45
(-2.90%)
Market Cap
2,381.20 Cr
EPS
13.67
PE Ratio
77.95
Dividend Yield
0.00 %
Industry
0.00
52 Week High
665.00
52 Week Low
435.25
PB Ratio
3.19
Debt to Equity
1.28
Sector
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Growth Rate
Revenue Growth
457.18 %
Net Income Growth
289.29 %
Cash Flow Change
-1,739.81 %
ROE
-23.80 %
ROCE
-50.08 %
EBITDA Margin (Avg.)
-51.25 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Dec 2024
Revenue
80
104
108
Expenses
64
80
77
EBITDA
16
24
31
Operating Profit %
19 %
22 %
25 %
Depreciation
3
4
4
Interest
3
3
6
Profit Before Tax
10
18
21
Tax
3
3
4
Net Profit
7
14
16
EPS in ₹
4.01
5.22
5.04

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
59
131
622
Fixed Assets
7
27
235
Current Assets
27
51
251
Capital Work in Progress
8
35
97
Investments
15
17
0
Other Assets
29
53
289
Total Liabilities
59
131
622
Current Liabilities
10
52
248
Non Current Liabilities
13
34
143
Total Equity
37
46
232
Reserve & Surplus
28
36
174
Share Capital
9
10
31

Cash Flow

Cash Flow
2022
2023
2024
Net Cash Flow
2
-3
13
Investing Activities
-24
-48
-54
Operating Activities
-10
-1
-20
Financing Activities
37
46
87

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
66.66 %
45.76 %
45.76 %
45.77 %
FIIs
0.00 %
5.51 %
4.25 %
4.17 %
DIIs
0.00 %
18.61 %
11.78 %
9.65 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
31.43 %
Others
33.34 %
2.23 %
9.49 %
8.97 %
No of Share Holders
177
43,707
43,707
37,653

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A4 days ago
Update In Respect Of Our Intimations Dated March 11 2025 And March 12 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)5 days ago
Intimation For Change In Contact Details Of MUFG Intime India Private Limited Registrar And Share Transfer Agent (RTA) Of The Company.8 days ago
Intimation For Change In Corporate Identity Number (CIN) And Listing Status Of Senores Pharmaceuticals Limited (Company) On The Ministry Of Corporate Affairs (MCA) Portal.Apr 04, 2025
Intimation For Change In Corporate Identity Number (CIN) And Listing Status Of Senores Pharmaceuticals Limited (Company) On The Ministry Of Corporate Affairs (MCA) Portal.Apr 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of Corporate Guarantee.Apr 02, 2025
Announcement Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Issuance Of Corporate Guarantee.Apr 02, 2025
Closure of Trading WindowMar 27, 2025
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Mar 20, 2025
Additional Disclosure In Respect Of Our Intimation Dated March 11 2025 Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Mar 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionMar 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient (API) Manufacturing Facility Of The CompanyFeb 26, 2025
Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient (API) Manufacturing Facility Of The CompanyFeb 26, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 25, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 20, 2025
Intimation For Change In The Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of The Company.Feb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2025
Integrated Filing (Financial)Jan 23, 2025
Appointment of Secretarial AuditorJan 23, 2025
Monitoring Agency Report for the quarter ended December 31 2024Jan 23, 2025
Statement Of Deviation/Variation If Any For The Quarter Ended December 31 2024.Jan 23, 2025
Media Release For Q3 And 9MFY25Jan 23, 2025
Results For Quarter And Nine Months Ended December 31 2024Jan 23, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 23-01-2025.Jan 23, 2025
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.Jan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 10, 2025
Board Meeting Intimation for Considering And Approving Unaudited Standalone And Consolidated Financial Results Of The Company For Quarter And Nine Months Ended December 31 2024.Jan 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 09, 2025
Closure of Trading WindowDec 31, 2024
Listing of Equity Shares of Senores Pharmaceuticals LtdDec 30, 2024

Technical Indicators

RSI(14)
Neutral
40.01
ATR(14)
Less Volatile
30.47
STOCH(9,6)
Neutral
54.53
STOCH RSI(14)
Neutral
39.69
MACD(12,26)
Bearish
-3.20
ADX(14)
Weak Trend
18.70
UO(9)
Bearish
39.21
ROC(12)
Downtrend And Accelerating
-2.78
WillR(14)
Neutral
-51.61